Latent Autoimmune Diabetes in Adults in the United Arab Emirates: Clinical Features and Factors Related to Insulin-Requirement
Overview
Authors
Affiliations
Aims: To describe and to characterize clinical features of latent autoimmune diabetes in adults (LADA) compared to type 1 and type 2 diabetes in the UAE.
Methods: In this cross-sectional study a dataset including 18,101 subjects with adult-onset (>30 years) diabetes was accessed. 17,072 subjects fulfilled the inclusion/exclusion criteria. Data about anthropometrics, demographics, autoantibodies to Glutamic Acid Decarboxylase (GADA) and to Islet Antigen 2 (anti-IA2), HbA1c, cholesterol and blood pressure were extracted. LADA was diagnosed according to GADA and/or anti-IA2 positivity and time to insulin therapy.
Results: 437 (2.6%) patients were identified as LADA and 34 (0.2%) as classical type 1 diabetes in adults. Mean age at diagnosis, BMI, waist circumference, systolic blood pressure and HbA1c significantly differed between, LADA, type 2 and type 1 diabetes, LADA showing halfway features between type 2 and type 1 diabetes. A decreasing trend for age at diagnosis and waist circumference was found among LADA subjects when subdivided by positivity for anti-IA2, GADA or for both antibodies (p=0.013 and p=0.011 for trend, respectively). There was a gradual downward trend in autoantibody titre in LADA subjects requiring insulin within the first year from diagnosis to subjects not requiring insulin after 10 years of follow-up (p<0.001).
Conclusions: This is the first study describing the clinical features of LADA in the UAE, which appear to be different from both type 1 and type 2 diabetes. Furthermore, we showed that the clinical phenotype of LADA is dependent on different patterns of antibody positivity, influencing the time to insulin requirement.
The epidemiology of type 1 diabetes mellitus in older adults.
Tomic D, Harding J, Jenkins A, Shaw J, Magliano D Nat Rev Endocrinol. 2024; 21(2):92-104.
PMID: 39448829 DOI: 10.1038/s41574-024-01046-z.
Nolasco-Rosales G, Martinez-Magana J, Juarez-Rojop I, Rodriguez-Sanchez E, Ruiz-Ramos D, Villatoro-Velazquez J Int J Mol Sci. 2024; 25(18).
PMID: 39337639 PMC: 11432505. DOI: 10.3390/ijms251810154.
Mohammadi M Eur J Transl Myol. 2024; 34(3).
PMID: 39221599 PMC: 11487667. DOI: 10.4081/ejtm.2024.12694.
Herranz-Antolin S, Coton-Batres C, Lopez-Virgos M, Esteban-Monge V, Alvarez-de Frutos V, Torralba M Endocrine. 2024; 86(2):574-583.
PMID: 38844609 DOI: 10.1007/s12020-024-03901-5.
Aleman-Contreras R, Gomez-Diaz R, Noyola-Garcia M, Mondragon-Gonzalez R, Wacher N, Ferreira-Hermosillo A Life (Basel). 2024; 14(5).
PMID: 38792571 PMC: 11122504. DOI: 10.3390/life14050550.